Howard Gurney


  • 5481 Citations
  • 34 h-Index
1987 …2023
If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Howard Gurney is the Director of Clinical Trials for the Faculty of Medicine and Health Sciences at Macquarie University. 

Professor Gurney has a firm background in clinical research and has subspecialty interests in urogenital cancers including prostate, bladder, testis and kidney cancer. 

He has been the principal investigator for over 100 clinical trials and has published over 100 peer-reviewed articles in journals and book chapters.  Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area.  He is regarded as a leading authority on mechanisms for safe dosing of anticancer agents and has held research grants and has written a number of invited editorials on these topics. 

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Renal Cell Carcinoma Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Castration Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2023

Research Output 1987 2018

Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment

Attard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M. E. & on behalf of PLATO collaborators 1 Sep 2018 In : Journal of Clinical Oncology. 36, 25, p. 2639-2646 8 p.

Research output: Contribution to journalArticle

Open Access
Prostate-Specific Antigen
Prostatic Neoplasms
Control Groups

Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews

Van Leeuwen, M. T., Luu, S., Gurney, H., Brown, M. R., Webber, K., Pearson, S-A., Hunt, L. & Vajdic, C. M. 1 Jun 2018 In : BMJ Open. 8, 6, p. 1-6 6 p., e021064

Research output: Contribution to journalReview article

Open Access
Embolism and Thrombosis
Cerebrovascular Disorders
Peer Review

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer

Gao, B. , Lu, Y. , Nieuweboer, A. J. M. , Xu, H. , Beesley, J. , Boere, I. , De Graan, A. J. M. , De Bruijn, P. , Gurney, H. , Kennedy, C. J. , Chiew, Y. E. , Johnatty, S. E. , Beale, P. , Harrison, M. , Luccarini, C. , Conroy, D. , Mathijssen, R. H. J. , Harnett, P. R. , Balleine, R. L. , Chenevix-Trench, G. & 2 others MacGregor, S. & De Fazio, A. 1 Dec 2018 In : Scientific Reports. 8, 1, p. 1-10 10 p., 1508

Research output: Contribution to journalArticle

Open Access
Genome-Wide Association Study
Single Nucleotide Polymorphism
Drug Therapy

Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer

Vaughn, D. J., Bellmunt, J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Li, H., Perini, R. F., Bajorin, D. F. & de Wit, R. 1 Jun 2018 In : Journal of Clinical Oncology. 36, 16, p. 1579-1587 9 p.

Research output: Contribution to journalArticle

Quality of Life
Drug Therapy
Health Status
Research Personnel

Nivolumab in the treatment of advanced renal cell carcinoma

Arasaratnam, M. & Gurney, H. Jul 2018 In : Future Oncology. 14, 17, p. 1679-1689 11 p., 29460635

Research output: Contribution to journalReview article

Renal Cell Carcinoma